Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastrointest Surg. Feb 27, 2020; 12(2): 34-44
Published online Feb 27, 2020. doi: 10.4240/wjgs.v12.i2.34
Table 2 Statistical analysis of prognostic factors for overall survival
Demographic, clinical and pathological factorsOverall Survival [median (range) mo]Uni-variate analysisMulti-variate analysisRisk ratio (Confidence interval)
Age0.373
< 65 yr (n = 244)39 (3-165)
≥ 65 yr (n = 342)35 (3-160)
Gender0.236
Male (n = 389)35 (3-165)
Female (n = 197)38 (3-160)
Presentation0.189
Synchronous (n = 225)46 (4-165)
Metachronous (n = 361)31 (3-160)
Neutrophil-to-lymphocyte ratio36 (3-165)0.219
< 5 (n = 490)41 (4-153)
≥ 5 (n = 96)
Platelet-to-lymphocyte ratio0.902
< 150 (n = 287)34 (5-165) 41 (3-156)
≥ 150 (n = 299)
Neo-adjuvant chemotherapy37 (4-165)0.0020.0140.710 (0.541-0.933)
Yes (n = 135)37 (3-160)
No (n = 451)
Statin therapy0.459
Yes (n = 181)34 (3-160)
No (n = 405)38 (3-165)
Deprivation index0.324
1 (n = 101)31 (4-152)
2 (n = 120)38 (3-160)
3 (n = 115)31 (5-147)
4 (n = 142)41 (4-159)
5 (n = 108)36 (4-165)
Less than hemi-hepatectomy (n = 368)38 (3-165)0.0020.0041.441 (1.125-1.845)
Hemi-hepatectomy or more (n = 218)36 (3-160)
Largest tumour size0.079
< 5 cm (n = 406)38 (3-159)
≥ 5 cm (n = 180)33 (3-165)
Number of metastases0.0150.2161.171 (0.912-1.504)
Solitary (n = 294)40 (3-165)
Multiple (n = 292)34 (4-159)
Steatosis0.512
None (n = 426)32 (3-165)
Mild (n = 97)59 (5-154)
Moderate – severe (n = 63)67 (7-159)
Lymphatic invasion0.440
Positive (n = 67)56 (3-160)
Negative (n = 519)35 (3-165)
Vascular invasion0.130
Positive (n = 264)34(3-160)
Negative (n = 322)40 (4-165)
Peri-neural invasion< 0.0010.0020.521 (0.342-0.795)
Positive (n = 38)27 (3-101)
Negative (n = 548)38 (3-165)
Biliary invasion0.530
Positive (n = 181)37 (3-160)
Negative (n = 405)37 (4-165)
Resection margin (R0)< 0.0010.0041.462 (1.130-1.891)
R0 (n = 427)39 (3-165)
R1 (n = 159)34 (4-160)